Heme Oxygenase Inhibition Increases Blood Pressure in Pregnant Rats
Open Access
- 3 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 26 (7) , 924-930
Abstract
During normal gestation, the placenta is a relatively hypoxic organ and, as such, is subject to significant oxidative stress. In the preeclamptic patient, inadequate remodeling of the maternal vasculature severely exacerbates placental oxidative stress, which has been shown to be an important component of maternal hypertension. There is emerging evidence that Heme Oxygenase-1 (HO-1) acts as an important regulator of placental and cardiovascular function during normal pregnancy. Here, we have examined the effect of Heme Oxygenase (HO) inhibition in late gestation on maternal blood pressure, angiogenic balance, and placental oxidative stress in pregnant rats. HO activity was inhibited with tin mesoporphyrin (SnMP), which was administered on gestational day 14, and blood pressure was measured on gestational day 19. Placental angiogenic balance and plasma Vascular Endothelial Growth Factor (VEGF) were determined by sandwich enzyme-linked immunosorbent assay. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by lucigenin chemilluminescence. In response to SnMP treatment, maternal mean arterial pressure (MAP) was significantly increased (99±1 vs. 113±2mm Hg; P < 0.05; n = 15 per group). Placental soluble fms-like tyrosine kinase-1 (sFlt-1) (631±47 vs. 648±26 pg/mg; P = 0.76) levels in the placenta were not affected by HO inhibition. Additionally, there was no significant difference in free VEGF in the maternal circulation (287±22 vs. 329±14 pg/ml; P = 0.11). There was, however, a significant decrease in placental VEGF (23±2 vs. 16±1 pg/mg; P < 0.05) and a significant increase in placental NADPH oxidase activity in SnMP-treated rats (2021±238 vs. 3005±301 RLU/min/mg; P < 0.05). Our results demonstrate that HO is an important regulator of blood pressure and an important antioxidant in the developing placenta.Keywords
This publication has 40 references indexed in Scilit:
- Bilirubin, Renal Hemodynamics, and Blood PressureFrontiers in Pharmacology, 2012
- Heme Oxygenase-1 Attenuates Hypoxia-Induced sFlt-1 and Oxidative Stress in Placental Villi through Its Metabolic Products CO and BilirubinInternational Journal of Hypertension, 2011
- Maternal Heme Oxygenase 1 Regulates Placental Vasculature Development via Angiogenic Factors in Mice1Biology of Reproduction, 2011
- Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced HypertensionHypertension, 2011
- Role of Reactive Oxygen Species During Hypertension in Response to Chronic Antiangiogenic Factor (sFlt-1) Excess in Pregnant RatsAmerican Journal of Hypertension, 2011
- A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic useJournal of Cellular and Molecular Medicine, 2010
- Effect of Heme Oxygenase-1 Deficiency on Placental DevelopmentPlacenta, 2009
- Identification of Novel Trophoblast Invasion-Related Genes: Heme Oxygenase-1 Controls Motility via Peroxisome Proliferator-Activated Receptor γEndocrinology, 2009
- Role of Reactive Oxygen Species in Hypertension Produced by Reduced Uterine Perfusion in Pregnant RatsAmerican Journal of Hypertension, 2008
- Bilirubin inhibits the activation of superoxide-producing NADPH oxidase in a neutrophil cell-free systemBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1991